AGT

Across TCGA pan-cancer cohorts, AGT mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AGT data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AGT mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AGT expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where AGT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.504	0.977	.005	28	view →
CCRCC	DFS	Quartile	III,IV	0.791	0.323	.004	24	view →
LSCC	OS	Quartile	All	0.898	1.000	.016	9	view →
HNSC	OS	Median	All	0.956	1.000	.014	6	view →
UCEC	DFS	Quartile	II,III,IV	0.509	1.000	.025	4	view →
PDAC	OS	Median	All	0.793	0.930	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AGT–LUAD (DFS)

Open the LUAD breakdown →